At CD BioSciences, our FISH and Hematologic Oncology Testing solutions provide integrated, high-precision cytogenetic and immunophenotyping services for comprehensive hematologic malignancy evaluation. Combining advanced Fluorescence In Situ Hybridization (FISH) assays with state-of-the-art multiparameter flow cytometry, we assist biopharmaceutical sponsors and clinical researchers in precise tumor subtyping, risk stratification, prognosis assessment, target therapy selection, and Minimal Residual Disease (MRD) monitoring.

Supported by experienced hematopathologists and compliant laboratory infrastructure, we process diverse biological sample types—including peripheral blood, bone marrow aspirates, fine-needle aspirates (FNA), CSF, and FFPE tissues—ensuring rapid turnaround times, rigorous data quality, and actionable biomarker insights across all drug development stages.